PRLD
NASDAQ · Biotechnology
Prelude Therapeutics Inc
$5.33
+0.40 (+8.11%)
Open$4.90
Previous Close$4.93
Day High$5.69
Day Low$4.90
52W High$5.54
52W Low$0.75
Volume—
Avg Volume405.1K
Market Cap336.90M
P/E Ratio—
EPS$-0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+76.7% upside
Current
$5.33
$5.33
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.81M | 132.26M | 127.36M |
| Net Income | -104,958,450 | 2.80M | 2.65M |
| Profit Margin | -819.6% | 2.1% | 2.1% |
| EBITDA | -108,497,926 | 4.42M | 4.16M |
| Free Cash Flow | — | 2.17M | 2.21M |
| Rev Growth | — | +3.8% | -1.6% |
| Debt/Equity | — | 0.63 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |